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PEXPEDITED REVIEWS Viewpoint
C-Reactive Protein and the
Prediction of Cardiovascular
Events Among Those at Intermediate Risk
Moving an Inflammatory Hypothesis Toward Consensus
Paul M Ridker, MD, MPH, FACC
Boston, Massachusetts
Over 20 large-scale prospective studies show that the inflammatory biomarker high-sensitivity C-reactive protein
(hsCRP) is an independent predictor of future cardiovascular events that additionally predicts risk of incident
hypertension and diabetes. In many studies, the relative impact of hsCRP is at least as large as that individually
of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, blood pressure, or smoking, and
knowledge of hsCRP correctly reclassifies a substantial proportion of “intermediate-risk” individuals into clinically
relevant higher- or lower-risk categories. Other studies show the relative benefit of statins to be greater among
those with increased hsCRP and that achieved hsCRP levels after statin therapy predict recurrent event rates as
much as achieved levels of low-density lipoprotein cholesterol. Nonetheless, it remains controversial whether the
time has come to modify traditional algorithms used for global risk detection. As described here, 6 areas of con-
troversy regarding hsCRP are resolvable with a consensus position that focuses in primary prevention on selec-
tive use among individuals with 5% to 20% 10-year risk as estimated by Adult Treatment Panel III, and focuses
in secondary prevention on high-risk patients being treated with statin therapy. Forthcoming trial data could ex-
pand or contract this “screen selectively” policy, and investigators should be open to the possibility that second-
generation inflammatory biomarkers may be developed that supplant hsCRP altogether. In the meantime, how-
ever, this consensus position on hsCRP should be one to which both advocates and critics of the inflammatory
hypothesis of atherosclerosis can adhere because it is one that can immediately improve patient care.
(J Am Coll Cardiol 2007;49:2129–38) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.0521
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wxactly 10 years ago it was reported that the inflammatory
iomarker C-reactive protein, when measured in blood with
high-sensitivity assay (hsCRP), is a strong, independent
redictor of future myocardial infarction and stroke among
pparently healthy asymptomatic men, and that the magni-
ude of this effect was similar to that of cholesterol and
lood pressure (1,2). That work showed that inflammation,
s reflected in the concentration of hsCRP, preceded the
nset of cardiovascular events rather than being a result of
schemia or smoking as previously assumed (3–6), and thus
rovided evidence confirming the hypothesis that athero-
hrombosis was, in part, an inflammatory disorder (7–9).
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007, accepted February 13, 2007.Since that report from the Physicians Health Study in
997, the ability of hsCRP to predict myocardial infarction,
schemic stroke, and vascular death has been confirmed in
ore than 20 diverse population cohorts including the
omen’s Health Study (10–12), a general population
ohort from Britain (13), the WHI (Women’s Health
nitiative)-observational cohort (14), the Honolulu Heart
tudy (15), the NHS (Nurses Health Study) (16), the
PFUS (Health Professionals Follow-Up Study) (16), the
ONICA (Monitoring Trends and Determinants in Car-
iovascular Disease)-Augsberg cohort (17,18), the ARIC
Atherosclerosis Risk in Communities) study (19), the CHS
Cardiovascular Health Study) (20), the SHS (Strong Heart
tudy) (21), the Kuopio Ischemic Heart Disease Risk
actor Study (22), and the EPIC (Evaluation for Prevention
f Ischemic Complications)-Norfolk cohort (23). Further
ork has shown elevated hsCRP to modify risk associated
ith metabolic syndrome (24–26) and to predict incident
ype 2 diabetes (27–29) as well as hypertension (30,31). In
002, on the basis of data from 27,939 initially healthy
omen followed up over a decade, plasma levels of hsCRP
1 mg/l, 1 to 3 mg/l, and 3 mg/l were established as
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C-Reactive Protein and Risk Prediction May 29, 2007:2129–38representing lower, average, or
higher relative vascular risk when
added to traditional risk factors
(12). After a comprehensive as-
say standardization program was
completed by the Centers for
Disease Control and Prevention,
a panel of prevention experts pre-
sented in 2003 the first guidelines
for use of commercial hsCRP tests
as an adjunct to global risk predic-
tion (32).
More recently, the addition of
hsCRP to traditional risk factors
as been shown to reclassify up to 30% of individuals at
intermediate risk” into clinically relevant higher- or lower-
isk categories, and that the relative impact of hsCRP on
rediction is at least as large as that individually of low-
ensity lipoprotein (LDL) cholesterol, high-density li-
oprotein (HDL) cholesterol, blood pressure, or smoking
33). In fact, as shown in the recently published Reynolds
isk Score (34), 2 key biomarkers, hsCRP (reflecting
nflammation) and family history (reflecting genetic predis-
osition), not only reclassify nearly 50% of all women with
dult Treatment Panel III (ATP-III) estimated 5% to 10%
nd 10% to 20% 10-year risk into higher- or lower-risk
ategories, but do so with markedly improved accuracy (35).
ther data show that hsCRP is effective at predicting
ncident peripheral arterial disease in the general population
36,37) as well as vascular complications among diabetic
atients (38,39), those undergoing hemodialysis and peri-
oneal dialysis (40–42), and those undergoing bypass sur-
ery or percutaneous coronary angioplasty (43,44). Many
dditional studies confirm the utility of hsCRP for predic-
ion of ischemic stroke, a condition in which lipid levels are
ess effective (15,45–48). Because hsCRP has been impli-
ated in progression of carotid and cortical small vessel
isease (49,50), these observations suggest an even larger
ole for inflammation in the cerebral vasculature. Finally,
sCRP levels track with abdominal obesity, insulin resis-
ance, and the number of components of the metabolic
yndrome that are present. Yet, despite this concordance,
ultiple studies show that individuals formally qualifying
or metabolic syndrome by current criteria who have hsCRP
3 mg/l are at higher risk for future cardiovascular events
nd diabetes compared with those with metabolic syndrome
ho have hsCRP 1 mg/l, a risk relationship almost
dentical to that for hsCRP among individuals without
etabolic syndrome (24–26).
Based on this consistent body of evidence, many physi-
ians measure hsCRP as an adjunct to global cardiovascular
isk prediction, and an intensive search has been initiated for
argeted vascular anti-inflammatory agents that might have
fficacy in the treatment and prevention of coronary disease.
owever, there is ongoing debate regarding whether or not
Abbreviations
and Acronyms
ATP  Adult Treatment
Panel III
HDL  high-density
lipoprotein
hsCRP  high-sensitivity
C-reactive protein
LDL  low-density
lipoprotein
ROC  receiver-operator
characteristiche time has come to modify traditional algorithms used for ihe global detection of vascular risk (51). Over the past
ecade, 6 areas of controversy have framed much of this
ebate. As will be described, these controversies are largely
esolvable such that a consensus position on hsCRP can be
eached that both advocates and critics of the inflammation
ypothesis can adhere to and will ultimately improve
atient care.
esolving the Framingham Heart Study
nd Reykjavik Heart Study Controversies
igure 1 shows the predictive value in 14 apparently healthy
opulations with baseline hsCRP levels of 1 mg/l, 1 to 3
g/l, and 3 mg/l after adjustment for traditional risk
actors. All show similar efficacy with no evidence of
eterogeneity. Nonetheless, reports from 2 of these cohorts
enerated controversy because they did not seem to affirm
hese data, at least as initially published. Of these, the
ramingham Heart Study data are the most important
ecause they represent a cohort that is the basis for most
lobal risk prediction models.
Three presentations from the Framingham investigators
re highlighted here. In the first, Rost et al. (46) published
ramingham data in which risk of stroke or transient
schemic attack for men and women with baseline CRP
evels in the top quartile were 2.0 and 2.7 times higher,
espectively, when compared with those in the lowest
uartile, effects that remained significant for both genders
fter adjustment for smoking, total:HDL cholesterol, sys-
olic blood pressure, and diabetes. This article was followed
n 2005 by a second Framingham manuscript that again
ound CRP to be an important predictor of cardiovascular
isk in age- and gender-adjusted models, but was inter-
reted less optimistically because these effects were attenu-
ted and no longer significant after full multivariate adjust-
ent (52). Although often cited as a null paper, that analysis
nfortunately was performed with a non–high-sensitivity
ssay for CRP, and thus a true test of the inflammation
ypothesis in Framingham required repeat testing with an
ppropriate hsCRP assay. That re-analysis was presented as
n abstract at the November 2006 meeting of the American
eart Association. As reported, the age- and gender-
djusted relative risks in Framingham for hard cardiovascu-
ar events among individuals with baseline blood levels of
sCRP 1 mg/l, 1 to 3 mg/l, and 3 mg/l were 1.0
referent), 1.5, and 2.9, highly significant observations
ntirely consistent with earlier work. Moreover, this re-
nalysis showed that the fully adjusted relative risks among
hose with increasing levels of hsCRP were 1.0 (referent),
.2, and 1.7, again a highly significant finding (53). Thus,
ad an appropriate high-sensitivity assay been used origi-
ally, there would never have been any controversy between
ata from the Framingham Heart Study and data presented
y earlier investigators.
A second cohort that generated controversy at the time ofts publication was the Reykjavik Heart Study (54). This
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May 29, 2007:2129–38 C-Reactive Protein and Risk Predictioncelandic cohort began in 1967 in a population with high
ipid levels and thus is a comparison of hsCRP with usual
isk factors in an era that preceded effective public health
ecommendations to reduce fat intake. The investigators of
he Reykjavik Heart Study did not report outcomes by
sCRP levels of1 mg/l, 1 to 3 mg/l, and3 mg/l, but did
eport multivariate adjusted evidence showing that individ-
als with hsCRP in the highest tertile were significantly
ore likely to suffer future vascular events when compared
ith those in the lowest tertile (relative odds 1.5, 95%
onfidence interval [CI] 1.3 to 1.7). Despite this statistically
ignificant result, the Reykjavik report concluded that
sCRP was not clinically meaningful as this effect was
modest” in magnitude. However, in the same report, the
ultivariate adjusted odds ratio for systolic blood pressure
as also 1.5 (95% CI 1.3 to 1.7). Further, for those with
sCRP in the top fifth of the distribution (a level that
hould correlate closely with hsCRP 3 mg/l), the multi-
ariate adjusted odds ratio for hsCRP was 1.7 with 95% CIs
ompletely overlapping the risk associated with smoking
1.4 to 2.0). Thus, the impact of hsCRP in the Reykjavik
ata is in fact identical in magnitude to the impact of
ypertension and smoking in that population.
Subsequent to the Reykjavik data, 2 other European
ohorts presented prospective data on hsCRP in popula-
ions with more contemporary lipid levels, and both re-
Figure 1 Independent Impact of hsCRP on Cardiovascular Risk
Multivariate adjusted relative risks of future cardiovascular events according to ba
3 mg/l in 14 major prospective cohort studies. Data adapted from references 1,
 Cardiovascular Health Study; EPIC  Evaluation for Prevention of Ischemic Com
als Follow-Up Study; Iceland  Reykjavik Heart Study data; Kuopio  Kuopio Hear
study; NHS  Nurses Health Study; PHS  Physicians Health Study; PIMA  Pima
 Women’s Health Study.orted affirmative data. In the EPIC-Norfolk prospective aopulation (23), the fully adjusted odds ratio for future
ascular events among those with baseline hsCRP levels 3
g/l was 1.8 (95% CI 1.4 to 2.3), whereas the Kuopio
schemic Heart Disease Risk Factor Study of vascular
ortality reported a fully adjusted odds ratio of 2.9 (95% CI
.5 to 5.9) (22). Both of these contemporary European
ohorts found the impact of hsCRP to be at least as large as
hat of most usual risk factors, data fully consistent with
ther reports (55).
esolving the C-Statistic Controversy
espite the data in Figure 1, the impact of adding hsCRP
o model fit as measured by area under the receiver-operator
haracteristic (ROC) curve (and summarized by the
-statistic) is small, an observation that has led some to
onclude that hsCRP (and potentially other novel risk
actors for that matter) has little role in vascular disease
rediction (56–58). However, a careful analysis of the
-statistic and its role in prediction modeling suggests that
his is an incorrect conclusion and that the use of the
-statistic as a method of selecting variables for risk
rediction models may be ill advised (59).
The C-statistic is a technique designed to discriminate
etween cases and noncases in the setting of diagnostic
esting where disease already exists and where sensitivity
levels of high-sensitivity C-reactive protein (hsCRP) 1 mg/l, 1 to 3 mg/l, and
,16–20,22,23,51–54. ARIC  Atherosclerosis Risk in Communities study; CHS
ons-Norfolk study; FHS  Framingham Heart Study; HPFUS  Health Profession-
; MONICA  Monitoring Trends and Development in Cardiovascular Disease
n study; Strong  Strong Heart Study; UK  British general practice cohort; WHSseline
11–13
plicati
t Study
Indiand specificity are of clinical importance. The C-statistic,
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C-Reactive Protein and Risk Prediction May 29, 2007:2129–38owever, is a far less effective tool for selecting prediction
ariables when faced with a healthy population in which the
ask is to identify future disease where none currently exists.
s Cook (59) has recently shown, this technique can lead to
rroneous conclusions when applied to risk prediction in
rospective cohort data, particularly those involving healthy
ndividuals at risk for common disorders such as myocardial
nfarction or stroke.
By way of example, for an individual risk factor to
rovide adequate discrimination on its own as judged by
he C-statistic, it must have a hazard ratio of 16.0 or
reater (60). This fact, however, should not be construed
o imply that biomarkers with smaller hazard ratios are
ithout clinical utility. For example, a biomarker with an
djusted hazard ratio of 3.0 may be incapable of moving
he C-statistic, yet that same biomarker could in theory
ncrease a specific individual’s estimated 10-year risk
rom 8% to 24%, a reclassification of risk with major
mplications for treatment decisions. Moreover, other
han age, no component of the Framingham risk score
as an adjusted hazard ratio 3.0 (most, in fact, are
etween 1.6 and 2.0). As such, proponents of the
-statistic as the sole basis for selecting risk factors
ould, by necessity, also eliminate lipids, blood pressure,
nd perhaps even smoking from consideration as clini-
ally important. This paradox is particularly true for
holesterol, the core basis for pharmacologic interven-
ions proven to lower cardiovascular risk; were the same
Figure 2 Risk Reclassification Using hsCRP and Parental Histo
Impact of high-sensitivity C-reactive protein (hsCRP) (representing inflammation) an
representative population of 100,000 U.S. women at 5% to 10% and 10% to 20%
erences 34 and 35. BP  blood pressure; CVD  cardiovascular disease; HDLC riteria applied to total, LDL, and HDL cholesterol that ore now being applied to hsCRP, each of these would
ave erroneously been eliminated as a risk factor for heart
isease.
A more tenable position would be to acknowledge that
he C-statistic is an insensitive tool for selecting variables to
e included in risk prediction models based on prospective
ohort data of currently healthy individuals. Statisticians
ave suggested that additional methods can be used to
valuate model fit in this setting, including global measures
uch as the Bayes Information Criteria, Brier score, Yates
lope, and entropy (59,61). They also have emphasized that
ore attention should be paid in this setting to calibration
nd to reclassification (59,62–64).
Using these techniques, large and clinically important
ifferences between prediction models with and without
sCRP have been found, despite minimal effects on the
-statistic (33,35,53). This turns out to be of greatest
mportance for reclassifying individuals at intermediate
lobal risk using ATP-III criteria. For example, as shown in
igure 2, for a representative population of 100,000 U.S.
omen without diabetes (80,000 at 5% to 10% 10-year
isk and 20,000 at 10% to 20% 10-year risk by ATP-III),
dditional knowledge of hsCRP and family history would
lace 13,500 of these women at low risk, 48,500 at low to
oderate risk, 32,500 at moderate to high risk, and 5,400 at
igh risk. Moreover, in a direct comparison of estimated to
ctual event rates, this reclassification of risk has been shown
o be correct for well over 95% of those reclassified, despite
ily history (representing genetics) on estimates of global cardiovascular risk for a
r risk according to the Adult Treatment Panel III (ATP-III). Data adapted from ref-
density lipoprotein cholesterol; TC  total cholesterol.ry
d fam
10-yea
high-nly marginal effects on the C-statistic (35).
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May 29, 2007:2129–38 C-Reactive Protein and Risk Predictionesolving the Statin Controversy
n collaboration with the CARE (Cholesterol And Recur-
ent Events) Investigators, it was reported in 1998 that
ost-MI patients with elevated hsCRP levels had a greater
elative clinical benefit from statin therapy in secondary
revention when compared with those with lower hsCRP
evels (65). Soon thereafter, it was reported that statins
educe plasma levels of hsCRP in a manner largely inde-
endent of LDL reduction (66–68). Further, in collabora-
ion with the AFCAPS/TexCAPs (Air Force/Texas Coro-
ary Atherosclerosis Prevention Study) Investigators, the
bservation was made in primary prevention that individuals
ith elevated levels of hsCRP seemed to benefit from statin
herapy even when LDL cholesterol levels were not elevated
69).
Although initially controversial, the observation that
tatins lower hsCRP has been confirmed by multiple inves-
igators (70–74) and provides clinical support for the
ypothesis that in addition to lowering LDL cholesterol,
tatins might also have clinically relevant anti-inflammatory
ffects (75,76). On this basis, many physicians use hsCRP as
“tie-breaker” method to decide on statin use among
atient groups in which lipid-lowering therapy is considered
ptional by current ATP-III guidelines. In primary preven-
ion, such patients typically include those with LDL cho-
esterol between 130 and 160 mg/dl who also have 10% to
0% 10-year risks and are not diabetic. The use of hsCRP
or this purpose seems to provide a method of better
Figure 3 LDL Cholesterol, hsCRP, and Clinical Outcomes on St
Cumulative rates of recurrent myocardial infarction or cardiovascular death among
achieved levels of hsCRP in mg/l in the PROVE-IT–TIMI-22 (Pravastatin or Atorvast
(left) and in the A to Z (Aggrastat to Zocor) trial (right). Data adapted from ref
lipoprotein.argeting statins to the most appropriate higher-risk indi- riduals, an effect that would both maximize benefit and
inimize risk.
A second statin controversy was raised when investigators
n the PROVE-IT–TIMI-22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis in Myo-
ardial Infarction-22) trial presented a prespecified analysis
ddressing whether best clinical outcomes were obtained
mong acute coronary syndrome patients treated with st-
tins who had LDL cholesterol reduced below 70 mg/dl or
ho had hsCRP levels reduced below 2 mg/l, the approx-
mate median values for both variables after 30 days of
herapy (77). In that analysis of 3,745 patients, rates of
ecurrent myocardial infarction or cardiovascular death were
owest when both of these target goals was achieved (Fig. 3,
eft). However, when only the LDL cholesterol 70 mg/dl
arget or only the hsCRP 2 mg/l target was achieved, risk
eductions were less impressive (and the worst outcomes
ere observed when neither target was attained). These
ffects were independent of other determinants of outcome
ncluding age, gender, smoking, diabetes, hypertension,
besity, HDL cholesterol, peak creatine kinase leak,
illip class, use of early revascularization, and left ven-
ricular ejection fraction. On this basis, it was hypothe-
ized that among very-high-risk patients undergoing
tatin therapy, the dual goals of LDL and hsCRP
eduction should be considered a new clinical target for
herapy (78). In a follow-up analysis of PROVE-IT–
IMI-22, achieving low levels of hsCRP after initiation
f statin therapy was further found to be associated with
herapy
-treated patients according to achieved levels of LDL cholesterol in mg/dl and
aluation and Infection Therapy–Thrombolysis in Myocardial Infarction-22) trial
s 77 and 80. hsCRP  high-sensitivity C-reactive protein; LDL  low-densityatin T
statin
atin Ev
erenceeduced risks of stroke (79).
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C-Reactive Protein and Risk Prediction May 29, 2007:2129–38As with any controversial hypothesis, these data required
ndependent confirmation. Recently, the A to Z (Aggrastat
o Zocor) Investigators also found that achieving the dual
oal of LDL cholesterol 70 mg/dl and hsCRP 2 mg/l
as associated with the best clinical outcomes among 3,813
cute coronary syndrome patients initiating statin therapy
80); as shown in Figure 3 (right), this effect in the A to Z
rial was virtually identical to that found in PROVE-IT–
IMI-22. Moreover, in an analysis of the REVERSAL
Reversal of Atherosclerosis With Aggressive Lipid Lower-
ng Therapy) trial that used intravascular ultrasound to
easure disease progression over 18 months of statin
herapy, individuals who achieved below median levels of
oth LDL and hsCRP achieved the greatest coronary
theroma regression (81). This surrogate biomarker data
upports hard end point data from PROVE-IT–TIMI-22
nd A to Z, as well as data showing that those in whom
oth LDL cholesterol and hsCRP are reduced on statin
herapy are also those with the least progression of carotid
ntimal medial thickness (82). These confirmations show
hat initial observations regarding statins and hsCRP are
eproducible and consistent (83). Not all LDL-lowering
herapies reduce hsCRP. For example, ezetimibe given as
onotherapy has no impact on hsCRP, although when
iven concomitantly with a statin it seems to augment CRP
eduction.
For primary prevention patients with LDL cholesterol
elow 130 mg/dl who are at increased risk on the basis of
levated hsCRP, it remains unproven whether statin therapy
ill effectively reduce vascular event rates. To address this
ssue, the multinational JUPITER (Justification for the Use
f statins in Primary prevention: an International Trial
valuating Rosuvastatin) trial was launched in 2003 com-
aring rosuvastatin with placebo among 17,800 primary
revention patients with LDL cholesterol 130 mg/dl who
lso have hsCRP 2 mg/l (84). This trial has completed
nrollment and is designed to complete after approximately
00 end points have accrued.
esolving the Biological Variation Controversy
lasma levels of hsCRP acutely increase during stress,
hether ischemic or because of major trauma or infection.
his biological variance has led some critics to suggest that
sCRP measurement cannot be an effective clinical tool.
elow is a summary of evidence addressing this concern.
First, marked variation in hsCRP levels would have
mposed a major bias toward the null hypothesis in all of the
forementioned early epidemiologic studies in which only a
ingle baseline hsCRP measure was obtained. As such, the
bserved relative risks consistently seen in these studies will,
f anything, be underestimates of the true relative risk
ssociated with inflammation in the vascular disease process.
oreover, as suggested in the 2003 American College of
ardiology/American Heart Association guidelines for in-
ammatory biomarker use (32), evaluating hsCRP on 2 pccasions separated by a few weeks (as is also recommended
or lipids) greatly reduces any such variation in usual clinical
ractice.
Second, hsCRP levels are stable over long periods of
ime. In the CARE trial, the age-adjusted correlation
oefficient for hsCRP measured at baseline and after 5 years
f follow-up among individuals allocated to placebo was
.60, a level of correlation greater than that of total
holesterol, LDL cholesterol, or triglycerides (66). Simi-
arly, for 2,834 participants in the AFCAPS/TexCAPs trial
reated with placebo, there was no difference between
edian hsCRP levels at baseline and after 1 year of
ollow-up (69). Finally, among 379 participants in the
eykjavik Heart Study who provided paired samples over a
ecade apart, the within-person correlation coefficient for
sCRP was 0.59, identical to that of total cholesterol (0.60)
54). In all of these studies, the reported correlation coeffi-
ients for repeated hsCRP levels were similar to if not
uperior to that of repeated blood pressure measurements,
nother risk marker commonly used in global prediction
odels.
Despite this consistency of hsCRP levels over time, the
otential for biologic variation has led to misunderstanding
egarding the predictive value of chronically high levels of
sCRP. Published data indicate that individuals with very
igh levels of hsCRP (ranging between 10 and 60 mg/l on
chronic basis) are in fact at markedly high risk for future
ascular events, and that the impact of hsCRP on risk is
inear across a full range of hsCRP levels in a manner
nalogous to that of LDL cholesterol (85). Thus, although
t is appropriate to repeat hsCRP testing for values in excess
f 5 mg/l (and to use the lower of the 2 measurements for
linical decision making), individuals with substantially
ncreased levels on a chronic basis should not be considered
alse-positive because they are at high risk for future
ardiovascular events.
esolving the “Marker or
echanism” Controversy
ontroversy exists regarding whether CRP is only a clini-
ally useful determinant of disease, or whether it also may
lay a causal role in the atherothrombotic process (86,87).
hose who have proposed a causal role for CRP note that
RP promotes endothelial cell activation and dysfunction,
as substantive effects on vascular smooth muscle cells and
eointimal formation, and directly affects monocyte and
acrophage activity as well as matrix metalloproteinase
unction (88–93). Further, human CRP infusion studies
how both proinflammatory and prothrombotic effects (94),
hereas in transgenic mouse models, CRP seems to increase
hrombosis rates after vascular injury (95). From a genetic
erspective, CHS investigators have found that specific
olymorphisms in the CRP gene associate with plasma
evels of CRP and predict future events, data suggesting a
otentially causal link between CRP and atherothrombosis
(
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May 29, 2007:2129–38 C-Reactive Protein and Risk Prediction96). The CRP also may block the effect of leptin on satiety
nd weight gain, suggesting a novel mechanism for leptin
esistance (97). Some of these findings are controversial,
owever, and those who argue that CRP is not a causal
eterminant of atherothrombosis correctly note that no data
irectly showing that CRP reduction reduces vascular risk
re yet available. Further, because the liver is a major source
f CRP production and because CRP levels will increase
ith secretion of cytokines such as interleukin-6 from
everal tissues including adipocytes, CRP may only be a
econdary messenger of the inflammatory process.
The “marker versus mechanism” debate remains open and
s an area with a need for more research. Most importantly,
here is a need to develop novel CRP inhibitors that can be
sed to test directly whether CRP reduction results in
educed event rates. One such agent has been described and,
t least in animal models, has shown promise (98).
That being said, it is not necessary for any particular
iomarker to fulfill the Koch postulates before being useful
n a clinical setting. Even if CRP proves not to be causally
elated to atherothrombosis, it could remain a highly effec-
ive adjunctive method for the detection of cardiovascular
isk, particularly when LDL cholesterol levels are normal or
ow. By way of example, physicians routinely measure HDL
holesterol to assist in risk detection despite a lack of
vidence that increasing HDL improves clinical outcomes.
ebate concerning mechanistic properties of CRP should
ave little bearing on its utility as a clinically effective
iomarker for risk detection.
oving Toward a Consensus: Resolving
he “Screen Everyone” Versus “Screen
hose at Intermediate Risk” Controversy
alf of all heart attacks and strokes in the U.S. occur among
hose without hyperlipidemia, and between 15% and 20%
ccur among individuals who additionally do not smoke or
uffer from hypertension or diabetes (99). These data, along
ith the observation that higher levels of hsCRP predict
ascular risk even when lipid levels are low, have led to an
dditional controversy in the hsCRP literature that relates
o the selection of whom to screen. In essence, that
ontroversy can be summarized as “screen everyone” versus
screen selectively” focusing on those at intermediate global
isk.
Those who advocate a “screen everyone” position note
hat because current guidelines suggest screening all indi-
iduals for total cholesterol and HDL cholesterol as well as
lood pressure, the same should hold for hsCRP because the
agnitude of risk is similar and equally independent.
urther, the finding of an isolated but persistently marked
levation of hsCRP should raise clinical concern regarding
ascular risk in a manner analogous to that of isolated
yperlipidemia or hypertension. A “screen everyone” ap-
roach may also be cost-effective because the test itself is far
ess expensive than a return physician visit to review initialipid findings (100). From a patient perspective, this ap-
roach would eliminate the need for a second phlebotomy
and third physician contact) before risk level is computed.
ecause risk assessment should ultimately occur in the
rimary care physician’s office, these issues have spurred
nterest in on-site finger stick evaluation for hsCRP analo-
ous to that currently available for total cholesterol and
DL cholesterol.
A more conservative view that I favor is a “screen
electively” policy for hsCRP that focuses on primary
revention for those at 5% to 20% 10-year risk as estimated
y ATP-III risk factors, and focuses on secondary preven-
ion for high-risk patients being treated with statins when
chievement of low hsCRP levels along with low levels of
DL cholesterol portend best outcomes. Each of these
ositions has the advantage of being fully evidence based,
nd they are modest extensions of the intermediate-risk and
igh-risk recommendations made in 2003 by the American
eart Association/Centers for Disease Control and Preven-
ion panel at a time when far less data were available (32).
orthcoming data such as that from the JUPITER trial
ould expand or contract a “screen selectively” policy.
nvestigators should also be open to the possibility that
econd-generation inflammatory biomarkers may be devel-
ped that supplant hsCRP altogether.
Clear policy statements endorsing selective hsCRP use
mong these intermediate-risk and high-risk groups
ould contribute to consensus building in the epidemi-
logy and clinical community, as critics of the “screen
veryone” approach have agreed that selective screening
f intermediate-risk individuals is an evidence-based posi-
ion (101). After all, if the primary purpose of risk predic-
ion is to better inform our patients about their respective
eeds for dietary discretion, smoking cessation, exercise, and
ppropriate pharmacologic intervention, a more accurate
coring system should not be objectionable as long as it is
nexpensive and leaves the locus of control in the hands of
he primary care physician. Because those with 5% to 20%
0-year risk by current ATP-III algorithms represent the
roup in which clinical decision making is most complex,
oth patients and primary care providers stand to benefit
rom such a middle-ground position at this time.
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